North Carolina Translational & Clinical Sciences Institute (NC TraCS)

成立五年后，北方大学的临床和转化科学奖（CTSA） 卡罗莱纳州查佩尔山（北卡罗莱纳州），北卡罗来纳州州转化和临床科学研究所（NC TraCS）， 已成为一体化，校园范围内的家庭在临床和转化研究在斯坦福大学。整体 本U 54合作协议申请的目标是将联合收割机的研究优势、资源和 机会，并与新的合作伙伴，RTI国际（RTI），建立在基础上， CTSA的最后五年。NC TraCS将致力于通过加速临床和 从健康科学发现到向患者和社区传播的转化研究。NC TraCS将努力克服有效、持续翻译研究成果的障碍 通过提高效率、培训研究人员队伍，沿着转化研究的连续性进行发现 并将NC TraCS中开发的成功、经验证的方法出口到CTSA的其他机构， 公众拟议的CTSA将具体（1）扩大一个蓬勃发展的CTSA计划，以支持 临床和转化研究的全方位;（2）利用CTSA资源和机构 （a）下一代技术 改变临床研究和实践的本质，（B）新的范式和资源，以加速 药物开发，以及（c）强有力的比较有效性研究，以提供明确的证据 测试和治疗的好处和危害;（3）培训，支持和激励下一代 临床和转化科学研究人员的支持。这些目标将通过三种资源来实现， 在这方面，我们将继续努力，从原来的11项服务和三项战略举措中整合和精简服务。 现在，IBM和RTI拥有一套独特的研究和培训资源， 临床和转化研究，从基础科学到临床应用再到政策改变。NC TraCS将 利用CTSA申请的机会，获得超过6000万美元的配套机构投资， 支持扩大我们的能力，以实现这三个目标。通过与RTI的合作，NC TraCS将 利用它在过去五年中创造和培育的资源， 将研究成果带给全州的患者，以及通过CTSA联盟在全国范围内。 相关性（参见说明）; 长期以来，研究人员、临床医生和卫生政策专家一直在哀叹， 基础科学的发现，当这些发现到达患者手中， 好多了拟议的UNC-RTI伙伴关系与CTSA联盟合作将有助于确保 病人将更迅速和有效地从生物医学研究成果中受益。

Five years after its formation, the Clinical and Translational Science Award (CTSA) at the Univeristy of North Carolina at Chapel Hill (UNC), the North Carolina Translational and Clinical Sciences Institute (NC TraCS), has become the integrated, campus-wide home for clinical and translational research at UNC. The overall goal of this U54 Cooperative Agreement application is to combine the research strengths, resources and opportunities at UNC and new partner, RTI International (RTI), to build on the foundation established in the CTSA's last five years. NC TraCS will work to improve human health by accelerating clinical and translational research from health science discovery to dissemination to patients and communities. NC TraCS will strive to overcome the well-documented barriers to the effective, sustained translation of research discovery along the translational research continuum by improving efficiency, training a research workforce and exporting successful, validated methods developed in NC TraCS to other CTSA institutions and the public. The proposed CTSA will specifically (1) amplify a thriving CTSA program to the point that it supports the full spectrum of clinical and translational research; (2) leverage CTSA resources and institutional strengths to create a critical, sustained focus on three strategic initiatives: (a) next-generation technologies to transform the very nature of clinical research and practice, (b) new paradigms and resources to accelerate drug development, and (c) robust comparative effectiveness research studies to provide definitive evidence of the benefits and harms of tests and treatments; and (3) train, support and incentivize the next generation of clinical and translational science researchers. These goals will be accomplished by three resources, six services, integrated and streamlined from the original 11, and the three strategic initiatives. UNC and RTI now have a unique set of research and training resources to support the full range of clinical and translational research, from basic science to clinical application to policy change. NC TraCS will leverage the opportunity of this CTSA application to garner >$60 million dollars in matching institutional support to extend our capabilities to meet the three aims. In partnership with RTI, NC TraCS will take advantage of the resources it has created and nourished during the past five years to quickly and effectively bring the fruits of research to patients across the state, as well as nationally through the CTSA Consortium. RELEVANCE (See instructions); Researchers, clinicians and health policy experts have long lamented the well-documented lag between basic science discoveries and when those discoveries reach patients to treat them and make their lives better. The proposed UNC-RTI partnership in cooperation with the CTSA Consortium will help to ensure that patients will more quickly and effectively benefit from the results of biomedical research.